Skip to main content
ELUT logo

Elutia Inc (ELUT) Stock Price & Analysis

Elutia Inc (ELUT) — MoonshotScore 26/100 (Weak band), calculated Nov 18, 2026. Price $0.81 (-2.41%), as of the Nov 19, 2026 trading session; market cap $36.0M.

Educational signal · not a buy or sell recommendation · How to read this

$0.81 −$0.02 (-2.41%) Market Cap $36.0M

Elutia Inc · ELUT · NASDAQ

Elutia Inc. is a commercial-stage biotechnology company specializing in drug-eluting biologics for various medical applications, including neurostimulation and wound care.

Price as of Nov 19, 2026

Key Statistics

26 of 100

MoonshotScore v2 · Elutia (ELUT)

Weak
Business Quality Solid (64)
Financial Safety Okay (42)
Valuation Full (40)
Growth Durability Fading (39)
Momentum Rising (67)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak growth and a full valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Rising.

  • quarterly revenue $1M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 2 of the last 8 reports
  • Altman Z -6.26 · Piotroski F 5

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ELUT (57 recorded, newest six shown)
RecordedScoreBand
25Weak
26Weak
26Weak
26Weak
26Weak
26Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.81
Change on the day-2.41%
52-week range$0.50 – $1.39
Market capitalisation$36.0M—
Price / earnings (trailing)0.67
Shares traded on the day20.7K

Price & events

Other perspectives

Council score for Elutia (ELUT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Neutral
Growth Durability Weak
Momentum Moderate

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 28, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Negative
Debt/Equity Moderate
Gross Margin Moderate

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 8, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Elutia (ELUT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Elutia Inc (ELUT) is listed on NASDAQ. It employs 26 people and is led by C. Randal Mills. In Q3 FY2026 it reported revenue of $1M and net income of -$1M. The market values it at $36.0M.

2 · Latest results

What do the latest results show for Elutia (ELUT)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1M-$1M-$0.03 (diluted)
Q2 FY2026$2M-$8M-$0.18 (diluted)
Q1 FY2026$3M-$7M-$0.17 (diluted)
Q4 FY2025$3M$71M$1.48 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Elutia (ELUT)?

Short answer · as of

The distress and quality screens read Altman Z -6.26 · Piotroski F 5. Trailing ratios: ROE 267.7% · current ratio 2.63 · earnings yield 149.7%.

Data-derived red flags

  • Listing risk — at $0.81 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -6.26 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
5 · Peer comparison

How does Elutia compare with its peers?

Short answer

Elutia's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Intuitive Surgical, Inc. (ISRG) Named competitor$420.95 Nov 18, 2026$146B94 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Medtronic plc (MDT) Named competitor$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Elutia (ELUT) — this page$0.81$36.0M26

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ELUT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ELUT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Elutia (ELUT)?

Read these with our analysis →

Investor Questions: ELUT Stock

These answers are editorial: 1 of these 9 answers is drawn from the ELUT research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ELUT?

ELUT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ELUT a good stock to buy?

Stock Expert AI does not rate ELUT buy, sell or hold. Elutia Inc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ELUT stock price today?

The last price recorded for Elutia Inc (ELUT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ELUT?

Elutia Inc. faces several risks, including regulatory challenges that may impact the approval timeline for its products. Additionally, the company operates in a highly competitive environment, where larger firms may overshadow its market presence. Market adoption of new products also poses a risk, as healthcare providers may be hesitant to switch from established solutions.

What are the key factors to evaluate for ELUT?

Elutia Inc (ELUT) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. The regulatory landscape in the U.S. is evolving, with a growing emphasis on expedited pathways for breakthrough technologies, which Elutia can leverage to its advantage. Not financial advice.

How frequently does ELUT data refresh on this page?

ELUT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ELUT's recent stock price performance?

Elutia Inc (ELUT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin indicating strong operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ELUT overvalued or undervalued right now?

The trailing P/E of Elutia Inc (ELUT) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ELUT?

Fractional-share availability for Elutia Inc (ELUT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.